Project Grant R01HL183898
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $698K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Raleigh, NC 27607, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $166,924 on July 1, 2026, through the Cardiovascular Diseases Research program (CFDA 93.837) to support research on cell surface localization of Factor VIII mimetic therapy for hemophilia A treatment. The award funds a five-year project running through June 30, 2031, with work performed in Chapel Hill, North Carolina. The research addresses hemophilia A, an inherited bleeding disorder caused...
- The National Heart Lung and Blood Institute awarded $655,564 to the University of North Carolina at Chapel Hill on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop SPARKS-DCM, a multiscale computational modeling framework that integrates biochemistry, biophysics, and biomechanics of blood clotting with experimental data to predict mechanisms of action for procoagulant agents in platelet integrin disorders such as Glanzmann's thrombasthenia. The...
- The National Heart Lung and Blood Institute awarded the University of North Carolina at Chapel Hill $445,748 on August 15, 2026, to develop and validate a rapid diagnostic assay for hyperfibrinolysis in trauma patients under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of the Fibrinolytic Activation Screening Test (FAST), a five-minute plasma-based assay designed to detect fibrinolytic activation in trauma patients. Current whole blood viscoelastic...
- The National Heart, Lung, and Blood Institute awarded The Children's Hospital of Philadelphia $889,932 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to engineer and scale production of red blood cells derived from human induced pluripotent stem cells (iPSCs) for two high-impact applications: alloantibody detection and neonatal transfusion therapy. The project addresses urgent clinical needs in two vulnerable patient populations. Sickle cell disease...
- The National Heart, Lung, and Blood Institute awarded The Trustees of Columbia University in the City of New York $246,750 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate red blood cell transfusion characteristics in intracranial hemorrhage patients. The research examines how variations in red blood cell component and donor characteristics affect transfusion efficacy and patient outcomes in intracranial hemorrhage, a life-threatening condition...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $1,081,420 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic and translational research on platelet activation pathways and disorders of platelet count and function. The recipient will investigate cellular signaling pathways—particularly G proteins and integrin receptors—that control platelet adhesion and plug formation in hemostasis and...
- The National Heart, Lung, and Blood Institute awarded Children's Research Institute $1,818,088 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how postnatal hypoxemia—reduced blood oxygen levels present in cyanotic congenital heart disease—impacts cardiac maturation and surgical recovery outcomes in pediatric patients. The project will examine the interaction between hypoxemia, myocardial immaturity, and postoperative complications through...
- The National Heart, Lung, and Blood Institute awarded Emory University $221,270 on September 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of microvascular rheology and transfusion in thrombosis during sepsis. The award is a project grant with period of performance through August 31, 2027. The project uses state-of-the-art microfluidics assays to characterize how red blood cell aggregation and membrane deformability affect endothelial cell...
- The National Heart, Lung, and Blood Institute awarded Emory University $391,211 under the Cardiovascular Diseases Research program (CFDA 93.837) on June 1, 2026, to investigate alloimmune responses and anti-drug antibody formation against coagulation factor therapeutics in hemophilia patients. The research addresses inhibitor development—the formation of neutralizing antibodies against Factor VIII and Factor IX replacement therapies—which complicates treatment in approximately 30 percent of...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Trustees of Boston University $100,228 on December 12, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate enhancement of engraftment potential in human hematopoietic stem cells. The research addresses the challenge of preserving hematopoietic stem cell functionality during the ex vivo culture steps required for gene editing therapies. The project employs multi-modal profiling of...